ArticleCase reports in neurological medicine2026
Very Early Short-Course Cerebrolysin After Tenecteplase and Mechanical Thrombectomy: A Case Report.
Article in Case reports in neurological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Very Early Short-Course Cerebrolysin After Tenecteplase and Mechanical Thrombectomy: A Case Report.Case reports in neurological medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite high recanalization rates with mechanical thrombectomy (MT), large-vessel occlusion stroke results in death or dependency in over half of patients. Cerebrolysin, a multimodal neuropeptide preparation, may attenuate ischemia-reperfusion injury and support early neurorehabilitation. We report a 88-year-old woman with moderate prestroke disability who presented 2 h after the onset of right hemiparesis and aphasia due to M2 occlusion of the left middle cerebral artery. She received intravenous tenecteplase followed by MT, achieving complete reperfusion after three passes with no direct complications and no immediate clinical improvement. Directly postprocedure, cerebrolysin 30 mL/day was initiated as adjunctive treatment. Over the next 24 h, neurological deficits gradually resolved with no hemorrhagic transformation or evident infarct on follow-up CT. As the patient did not require early intensive rehabilitation and regained her prestroke functional status, cerebrolysin was discontinued after three doses. This report is not intended to establish the therapeutic efficacy of short-course adjunctive cerebrolysin. It illustrates how clinical signals from randomized and observational studies can be interpreted for the purpose of individual therapeutic decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.